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1Computational Genomics Department, Centro de Investigacion Prı́ncipe Felipe (CIPF), Valencia, Spain
2Medical Genome Project, Genomics and Bioinformatics Platform of Andalusia (GBPA), Sevilla, Spain
3Bioinformatics in Rare Diseases (BIER), Centro de Investigacion Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain
4Functional Genomics Node, National Institute of Bioinformatics (INB), Valencia, Spain
5Institut De Biologia Evolutiva, Consejo Superior de Investigaciones Cientı́ficas - Universitat Pompeu Fabra, Barcelona, Spain
6Department of Genetics, Reproduction and Fetal Medicine, Institute of Biomedicine of Seville, University Hospital Virgen del Rocı́o/
Consejo Superior de Investigaciones Cientı́ficas/University of Seville, Sevilla, Spain
7Centro de Investigacion Biomédica en Red de Enfermedades Raras (CIBERER), Sevilla, Spain
8Research and Development, 454 Life Sciences, a Roche Company, Branford, CT, USA
9Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland
10Roche Diagnostics SL, Sant Cugat del Vallès, Spain
11Departament of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
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Abstract
Recent results from large-scale genomic projects suggest that allele frequencies, which are highly relevant for medical
purposes, differ considerably across different populations. The need for a detailed catalog of local variability motivated
the whole-exome sequencing of 267 unrelated individuals, representative of the healthy Spanish population. Like in other
studies, a considerable number of rare variants were found (almost one-third of the described variants). There were also
relevant differences in allelic frequencies in polymorphic variants, including 10,000 polymorphisms private to the
Spanish population. The allelic frequencies of variants conferring susceptibility to complex diseases (including cancer,
schizophrenia, Alzheimer disease, type 2 diabetes, and other pathologies) were overall similar to those of other popu-
lations. However, the trend is the opposite for variants linked to Mendelian and rare diseases (including several retinal
degenerative dystrophies and cardiomyopathies) that show marked frequency differences between populations.
Interestingly, a correspondence between differences in allelic frequencies and disease prevalence was found, highlighting
the relevance of frequency differences in disease risk. These differences are also observed in variants that disrupt known
drug binding sites, suggesting an important role for local variability in population-specific drug resistances or adverse
effects. We have made the Spanish population variant server web page that contains population frequency information
for the complete list of 170,888 variant positions we found publicly available (http://spv.babelomics.org/), We show that
it if fundamental to determine population-specific variant frequencies to distinguish real disease associations from
population-specific polymorphisms.
Key words: population variability, exome sequencing, disease variants, pharmacogenomic variants.
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Introduction
Recent large-scale population genomic projects (Durbin et al.
2010; Fu et al. 2013) have revealed the existence of an enor-
mous amount of rare variation at the genome level in human
populations (Coventry et al. 2010; Li et al. 2010; Gravel et al.
2011; Marth et al. 2011; Keinan and Clark 2012; Nelson et al.
2012; Tennessen et al. 2012). In addition to the anticipated
neutral variation, apparently normal healthy individuals pre-
sent a considerable number of deleterious variants with a
putative effect on the function of human protein-coding
genes (Kryukov et al. 2007; MacArthur and Tyler-Smith
2010; Marth et al. 2011; Nelson et al. 2012; Tennessen et al.
2012; Xue et al. 2012; Garcia-Alonso et al. 2014) and functional
noncoding genomic elements, including miRNAs (Carbonell
et al. 2012) and other regulatory regions (Dunham et al. 2012;
Spivakov et al. 2012). Moreover, recent studies have described
a remarkable local component (Kryukov et al. 2007; Marth
et al. 2011; Nelson et al. 2012) and a high stratification level
(Mathieson and McVean 2012; Moreno-Estrada et al. 2013) in
many rare variants with uncertain functional consequences. It
is likely that these rare variants help explaining the differential
risk of many diseases in distinct human populations (Corona
et al. 2013; Fernandez et al. 2013). All of these observations
highlight the need for population-specific catalogs of genetic
variation (Bustamante et al. 2011).
Despite being systematically studied at the single nucleotide
polymorphism (SNP) level (Bustamante et al. 2011), sample sizes
for individual European populations (amounting to only 50–90
individuals per population) in large-scale genome sequencing
projects (Durbin et al. 2010) limit the precision at which their
genetic variation at nucleotide resolution level can be assessed.
Extensive variability surveys of European populations based on
SNPs show a clear correspondence between genetic and geo-
graphic distances (Novembre et al. 2008). On the other hand,
previous studies reported that the proportion of damaging sub-
stitutions is appreciably higher in individuals with European an-
cestry than in those with African ancestry (Barreiro et al. 2008;
Lohmueller et al. 2008; Vasseur and Quintana-Murci 2013),
which reinforces the need to gain insight into the degree of
genetic variation at the population level. To our knowledge,
only two initiatives that produced population-specific catalogs
of genetic variation have been published to date: a whole-
genome sequence (WGS) study of 100 Malays (Wong et al.
2013) and the recent Genome of the Netherlands with low-res-
olution (13) WGS data of 250 trio-families from across the
entire country (The_Genome_of_the_Netherlands_Consortium
2014). Another recent study of 109 exomes from French-
Canadians, descendants of a small number of French settlers,
show how the frequency of rare variants increases after popu-
lation bottlenecks (Casals et al. 2013).
Genomic data are providing an increasingly detailed per-
spective of the landscape of human variability at the nucleo-
tide resolution level (Goldstein et al. 2013). Precision medicine,
an emerging paradigm of medicine oriented to maximizing
individual care and disease prevention rather than merely
treating disease (Hood and Friend 2011), requires knowledge
about the genetic structure of human populations, particularly
in its preventive aspects (Khoury et al. 2012). Such knowledge
is also essential for identifying genetic factors contributing to
variation in disease risk as well as to drug pharmacokinetics,
treatment efficacy, and adverse drug reactions (Dopazo 2014).
Attempts to map the genetic basis of any of these disease traits
will likely produce spurious associations if the genetic structure
of the population is not properly accounted for (Price et al.
2006; Goldstein et al. 2013; Boomsma et al. 2014). Despite the
extensive use of targeted exome sequencing to discover dis-
ease genes in Mendelian disorders (Ng et al. 2010; Bamshad
et al. 2011) or cancer (Garraway and Lander 2013; Vogelstein
et al. 2013), lack of information about local genetic variation
can severely hinder the discrimination of real disease variants
from local polymorphisms and rare variants.
The classical consensus about the existence of relative ho-
mogeneity within European populations started to be ques-
tioned by genome-wide association studies (GWAS) reporting
a correspondence between genetic and geographic distances
(Novembre et al. 2008). Our observations support this view and
suggest that the level of variation in local populations, even in
the absence of geographic barriers, is higher than expected
from previous variability studies based on polymorphisms
(Novembre et al. 2008; Bustamante et al. 2011). A large pro-
portion of this variability corresponds to private variants, as
previously reported in several studies (Coventry et al. 2010; Li
et al. 2010; Marth et al. 2011; Keinan and Clark 2012; Nelson et al.
2012; Tennessen et al. 2012). Here, we have analyzed whole-
exome sequencing (WES) data from a sample of 267 healthy
individuals of Spanish origin, which allowed us to carry out an
exhaustive study of variability in the healthy Spanish population.
The individuals were used as controls in the Medical Genome
Project (MGP; http://www.medicalgenomeproject.com, last
accessed January 28, 2016), a public–private partnership which
aims to discover disease genes and mutations. Our analysis dis-
covered a high degree of local variability private to the Spanish
population, and a considerable difference in allele frequencies in
polymorphic variants relative to geographically close popula-
tions (e.g., Tuscans from Italy). These observations extend to
disease susceptibility or causal disease variants. Although allele
frequencies for complex diseases in the Spanish population
seem to be similar to other populations, the scenario for
Mendelian and rare diseases seems to be the opposite, with
significant differences in allele frequencies in the Spanish pop-
ulation (at least for several paradigmatic cases, including hered-
itary cardiomyopathies, degenerative retinal dystrophies, and
others). Interestingly, differences in the allelic distributions of
variants affecting known drug binding sites seem to be frequent,
which suggests that drug resistance, adverse effects, etc., may
have an important population-specific component. Finally, we
report an example illustrating the importance of local variation
to distinguish disease variants from local polymorphisms which
could otherwise be taken as rare variants.
Results
Collection of Healthy Individuals
Blood samples from a total of 267 unrelated individuals of
Spanish origin (obtained mainly in the North West—in
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Galicia—and in the South—in Andalusia—), who were phe-
notyped as healthy (i.e., with no known diseases or genetic
conditions in the family history), were collected (see Materials
and Methods).
Sequencing Results
The pipeline for primary data analysis (quality control and
mapping) is described in Materials and Methods. The ob-
served average coverage was satisfactory in all the samples
analyzed (above 40, which approximately corresponds to
the expected coverage). The frequency of the alternative allele
when the variant call was heterozygous was over 30% of the
reads. These results ensured the quality of the variant calling
process in this population.
Sequence data has been deposited at the European Genome-
phenome Archive (EGA, see http://ega.crg.eu, last accessed
January 28, 2016), under accession number EGAS00001000938.
Variability Distribution in the Spanish Population
A summary of the variability corresponding to the exonic re-
gions of the Spanish population is shown in table 1. Almost
one-third of the variants found had not been previously de-
scribed in dbSNP (Sherry et al. 2001), 1000 Genomes popula-
tions (1000G) (Durbin et al. 2010), or the National Heart, Lung,
and Blood Institute Exome Sequencing Project (Fu et al. 2013).
This level of discovery is similar to that previously observed in
other sequencing projects (Fu et al. 2013). A large proportion of
variants were found in only one individual in the Spanish pop-
ulation (85%), which also agrees with previous observations of
rare variant frequencies in different human populations
(Coventry et al. 2010; Li et al. 2010; Marth et al. 2011; Keinan
and Clark 2012; Nelson et al. 2012; Tennessen et al. 2012; Casals
et al. 2013). The average number of variants per individual in
the coding regions of the genome analyzed was 19,000.
Among these variants, the observed number of nonsynony-
mous changes per individual was 9,194. In particular, an average
of 95.8 stop gains and 29.4 stop losses per individual was ob-
served. There was also an average of 417.2 variants which affect
splicing. As observed in other large-scale genomic projects
(MacArthur and Tyler-Smith 2010; Xue et al. 2012), there
was an average of 352 likely deleterious nonsynonymous single
nucleotide variants (SNVs) (those which meet at least two of
the three pathogenicity indexes indicative of a potential dele-
terious effect; see Materials and Methods) per individual.
Among these, more than 50 variants per individual were ho-
mozygotes, therefore representing the presence of a consider-
able amount of potentially deleterious variation in the Spanish
population. Only 27.5% of the variants were already present in
the IBS population of 16 individuals, making 60.3% of the var-
iability we describe here new. The Spanish population variant
server web page contains the complete list of 170,888 variant
positions found in the Spanish MGP population sequenced in
this study, which can be interactively queried (http://spv.babe
lomics.org/, last accessed January 28, 2016).
Figure 1 depicts the extent of the variability of the Spanish
population captured by this study. The total number of new
variants present only in the Spanish population grew linearly
with the number of individuals analyzed and seemed to be far
from reaching a plateau in our study. However, when new
variants were decomposed into rare variants (singletons) and
polymorphic variants (those shared by several individuals) it
was apparent that the main contribution to the private
Spanish variability comes from rare variants, while polymor-
phic variants soon reached a plateau. This suggests that most
of the polymorphisms within coding regions, observed only in
the Spanish population, were apparently discovered in this
work and seem to be restricted to 10,000 positions.
Approximately, one-third of the variants found in the
Spanish population are homozygous. This proportion de-
creases to 7% if only Spanish-specific variants are considered.
The heterogeneity in the population can be viewed in supple
mentary figure S1, Supplementary Material online, and prob-
ably corresponds to different geographic locations.
Unfortunately, anonymization and randomization of the
samples (see Materials and Methods) precludes the assigna-
tion of specific samples to precise geographic locations.
The distribution pattern of homozygotes and heterozy-
gotes is consistent with a scenario in which most of the
Table 1. Variants in the Exonic Regions of the MGP Spanish Population.













Exome positions with SNV 170,888 18,875.8 6,906 63,243 835.8 59.4
Exome monoallelic positions 170,370 18,871.6 6,906 63,143 835.9 59.4
Exome multiallelic positions 518 4.2 0 100 0.8 0
Exome SNV 171,406 18,880.1 6,906 63,343 836.7 59.4
Singletons 54,214 202 59.4 54,214 202 59.4
Nonsynonymous SNV 97,589 9,193.7 3,335.5 40,564 538.6 41
Synonymous SNV 73,011 9,734 3,596.5 21,857 287.2 18
Stop gain SNV 1,852 95.8 22 1,060 15.9 0.4
Stop loss SNV 178 29.4 12 71 0.6 0.1
Splicing SNV 4,217 417.2 154.8 1,842 25.1 2
LoF SNV 32,736 1,163.8 211.2 17,314 141.8 3.3
LoF stricta SNV 12,639 352.6 51.4 7,136 51 0.3
aAll three pathogenicity predictors (SIFT, Polyphen, and conservation score) reported these SNVs as pathogenic, in contrast with loss-of-function (LoF) in which only two
pathogenicity predictions were required to consider the variant as pathogenic.
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variants are in Hardy–Weinberg equilibrium (Stern 1943).
Thus, at low allelic frequencies of the alternative allele, het-
erozygotes are prevalent, while the situation is the opposite at
high allelic frequencies, where many alternative alleles are
fixed in the population.
In summary, we observed an excess of low-frequency
nonsynonymous coding variants, most of them heterozy-
gotes, thus confirming the observations made in other pop-
ulations (Coventry et al. 2010; Li et al. 2010; Marth et al. 2011;
Keinan and Clark 2012; Nelson et al. 2012; Tennessen et al.
2012; Casals et al. 2013).
The Relationship of Spanish Populations
to Other Populations
Variants located in coding regions, with a minor allele fre-
quency (MAF) > 0.01 were used to carry out a principal
components analysis (PCA) analysis using the SNPRelate pro-
gram. Supplementary figure S2, Supplementary Material on-
line represents the two main axes of the PCA which depicts
the relationship between the MGP population and the dif-
ferent 1000G populations. As expected, the Spanish popula-
tion closely related to other European populations, with the
Italian (from Tuscany) population (TSI) being the closest.
Labels in the plot are located at the average of the coordinates
for each individual. As expected as well, the location of the
Spanish population in the plot coincides with the Spanish
individuals included in the 1000G project (IBS population).
Disease Variants and Disease Risk in
the Spanish Population
All 170,888 variant positions found in the 267 exomes of the
MGP population were screened for known disease variants
present in the Human Genome Mutation Database (HGMD,
commercial release 2011.4). We identified the presence of
3,069 variants annotated in the disease database. Among
them, 193 had MAFs in the Spanish population which ex-
ceeded those found in the 1000G populations by 2-fold (sup
plementary table S1, Supplementary Material online). When
compared with the 1000G subpopulation with European an-
cestry (the TSI, FIN, GBR, and CEU populations), 69 disease
variants still showed MAFs in the MGP population which
were at least 2-fold larger than those observed in European
ancestry populations (table 2). Some examples of familial
diseases with variants with remarkably high (between 4-
and 18-fold) allelic frequencies in Spain are: Marfan syndrome,
Von Willebrand syndrome, Ellis-van Creveld syndrome,
Wilson disease, cystinuria, Crohn’s disease, or Charcot-
Marie-Tooth disease, just to cite a few. In particular, several
degenerative retinal dystrophies seem to have associated mu-
tations at unusually high frequencies in the Spanish popula-
tion, such as the autosomal dominant cone dystrophy
(heterozygous in 4 out of the 267 Spanish samples but absent
in the 1000G populations), retinitis pigmentosa, Leber con-
genital amaurosis, Bardet–Biedl syndrome, and other ocular
diseases such as primary open angle glaucoma or Stargardt. All
these diseases showed significant differences in allele frequen-
cies among the populations compared when taking adjusted P
values<0.05 (supplementary table S1, Supplementary Material
online).
In contrast, the frequencies were more similar across all the
populations for variants which conferred susceptibility to
common diseases. There are several exceptions, in which a
particular variant, among the many associated with the dis-
ease, displayed remarkably higher allelic frequency in the
Spanish population when compared with the 1000G popu-
lations. Such cases include certain forms of diabetes, juvenile
Parkinsonism or late-onset Alzheimer (table 2 and supplemen
tary table S1, Supplementary Material online). Furthermore, a
few variants which have been associated with different types
of cancer also displayed comparatively high allelic frequencies
in the Spanish population, including variants for ovarian can-
cer, breast and ovarian cancer, retinoblastoma, and increased
melanoma risk, among others (table 2 and supplementary
table S1, Supplementary Material online). Variants associated
with other diseases with less severe symptoms also had com-
paratively high allelic frequencies in the Spanish population
(e.g., psoriasis and a type of autosomal dominant obesity).
There were also relatively underrepresented variants in the
Spanish population. As an anecdotal example, a variant asso-
ciated with red hair (CM003595, gene MC1R, which causes
both a nonsynonymous change and simultaneously affects an
exomic ncRNA) occurs at a low frequency (0.0037) in the
Spanish population compared with the relatively higher fre-
quency in the 1000G populations with European ancestry
(0.07). Similarly, variants associated with rare diseases also
showed remarkable differences in allelic frequencies in the
opposite direction. For example, the allele for the 2L form
of Charcot-Marie-Tooth disease is underrepresented in the
Spanish population (MAF 0.0037 versus 0.052 in 1000G, see
supplementary table S1, Supplementary Material online),
while the 2a form is overrepresented (see earlier). This is in
agreement with the observation that some diseases are
caused by different alleles in different populations
FIG. 1. Accumulative number of new variants contributed by indi-
viduals. The red line represents the number of variants found as the
number of sequenced individuals increase. The green line represents
the number of already known variants among all the variants found.
The blue line represents the number of new variants not present in
the 1000G populations. New variants are decomposed into polymor-
phic variants (present in more than one individual in the MGP pop-
ulation) represented by the blue dashed line, and rare variants
(present in only one MGP individual), represented by the blue dotted
line.
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Table 2. Variants Associated with Diseases That Have Allele Frequencies in the Spanish Population at Least 2-Fold Higher Than in the 1000G
Populations.
MGP 1000G
chr Start CT R A R/R R/A A/A MAF R/R R/A A/A MAF Ratio Ratio E HGMD_disease
22 36688178 ns G A 263 4 0 0.0075 1,078 0 0 0 NA NA Epstein syndrome?
6 42141500 ns C T 263 4 0 0.0075 1,078 0 0 0 NA NA Cone dystrophy, autosomal dominant
22 36688178 syn G A 263 4 0 0.0075 1,078 0 0 0 NA NA Epstein syndrome?
17 36104650 ns C A 264 3 0 0.0056 1,078 0 0 0 NA NA Diabetes, Maturity onset diabetes of the
young (MODY)
15 48704816 ns G A 262 5 0 0.0094 1,077 1 0 5.00E-04 18.8000 NA Marfan syndrome
6 162206852 ns G A 262 5 0 0.0094 1,077 1 0 5.00E-04 18.8000 NA Parkinsonism. juvenile. autosomal recessive
1 216420460 ns C A 263 4 0 0.0075 1,077 1 0 5.00E-04 15.0000 NA Retinitis pigmentosa. recessive.
no hearing loss
17 41199716 sg A T 264 3 0 0.0056 1,077 1 0 5.00E-04 11.2000 NA Ovarian cancer
19 8436373 ns C T 263 4 0 0.0075 1,076 2 0 9.00E-04 8.33333 NA Lower plasma triglyceride level
11 18050850 ns C T 263 4 0 0.0075 1,076 2 0 9.00E-04 8.33333 NA Attention deficit hyperactivity disorder
3 123376066 ns C T 263 4 0 0.0075 1,076 2 0 9.00E-04 8.33333 NA Aortic dissections?
7 107329557 ns T C 262 5 0 0.0094 1,075 3 0 0.0014 6.71429 NA Pendred syndrome
7 99032559 ns G A 250 17 0 0.0318 1,064 13 1 0.007 4.54286 12.23076 Complex I deficiency
18 2937867 ns C A 260 7 0 0.0131 1,075 3 0 0.0014 9.35714 10.07692 Psoriasis
15 58957371 ns C G 261 6 0 0.0112 1,076 2 0 9.00E-04 12.4444 8.615384 Alzheimer disease. late onset
15 42684875 nc C T 261 6 0 0.0112 1,072 6 0 0.0028 4.00000 8.615384 Muscular dystrophy. limb girdle
19 4159747 ns G A 262 5 0 0.0094 1,076 2 0 9.00E-04 10.4444 7.230769 Hypertriglyceridemia
12 6143978 ns C T 262 5 0 0.0094 1,075 3 0 0.0014 6.71429 7.230769 Von Willebrand. Normandy variant
1 115221116 ns C A 257 10 0 0.0187 1,073 5 0 0.0023 8.13043 7.192307 Adenosine monophosphate deaminase
deficiency
12 32994073 ns G A 257 10 0 0.0187 1,073 5 0 0.0023 8.13043 7.192307 Arrhythmogenic right ventricular
dysplasia/cardiomyopathy
4 5627493 syn G T 258 9 0 0.0169 1,074 3 1 0.0023 7.34783 6.5 Ellis-van Creveld syndrome
2 71825797 ns C G 263 4 0 0.0075 1,077 1 0 5.00E-04 15.0000 5.769230 Muscular dystrophy. limb girdle 2B
13 52534410 ns C T 263 4 0 0.0075 1,077 1 0 5.00E-04 15.0000 5.769230 Wilson disease
8 145699735 ns G C 263 4 0 0.0075 1,077 1 0 5.00E-04 15.0000 5.769230 Congenital heart defects
1 196709833 ns C T 263 4 0 0.0075 1,076 2 0 9.00E-04 8.33333 5.769230 Factor H deficiency
1 94568686 ns C T 263 4 0 0.0075 1,076 2 0 9.00E-04 8.33333 5.769230 Stargardt disease
5 110454719 ns A G 255 12 0 0.0225 1,074 4 0 0.0019 11.8421 5.625 Glaucoma. primary open angle
11 67799622 ns C T 260 7 0 0.0131 1,076 2 0 9.00E-04 14.5555 5.038461 Complex I deficiency
8 100832259 ns A G 260 7 0 0.0131 1,074 4 0 0.0019 6.89474 5.038461 Cohen sı́ndrome
1 183532364 ns T A 260 7 0 0.0131 1,071 7 0 0.0032 4.09375 5.038461 Chronic granulomatous disease
1 76211574 ns C A 264 3 0 0.0056 1,078 0 0 0 NA 4.307692 Medium chain acyl CoA
dehydrogenase deficiency
9 120475248 ns G A 261 6 0 0.0112 1,076 2 0 9.00E-04 12.444 4.307692 Meningococcal disease?
22 45691554 ns C T 264 3 0 0.0056 1,077 1 0 5.00E-04 11.200 4.307692 Renal adysplasia
11 88924465 ns C A 264 3 0 0.0056 1,077 1 0 5.00E-04 11.200 4.307692 Albinism. oculocutaneous 1
14 21811213 ns A G 264 3 0 0.0056 1,077 1 0 5.00E-04 11.200 4.307692 Leber congenital amaurosis
14 21811213 ns A G 264 3 0 0.0056 1,077 1 0 5.00E-04 11.200 4.307692 Retinitis pigmentosa?
13 48939088 ns C T 264 3 0 0.0056 1,077 1 0 5.00E-04 11.200 4.307692 Retinoblastoma
14 23862646 ns C A 264 3 0 0.0056 1,077 1 0 5.00E-04 11.200 4.307692 Cardiomyopathy. dilated
5 70945029 ns T C 261 6 0 0.0112 1,074 4 0 0.0019 5.89474 4.307692 Complex I deficiency
18 2925359 ns C T 245 22 0 0.0412 1,061 17 0 0.0079 5.21519 4.12 Psoriasis
6 31729925 ns C T 225 40 2 0.0824 980 87 11 0.0506 1.62846 4.12 Leukemia. risk. association with
17 56348226 sp T G 259 8 0 0.015 1,075 3 0 0.0014 10.7142 3.75 Myeloperoxidase deficiency
1 203194834 ns C T 262 5 0 0.0094 1,076 2 0 9.00E-04 10.444 3.615384 Chitotriosidase deficiency
16 16259579 syn G A 262 5 0 0.0094 1,075 3 0 0.0014 6.71429 3.615384 Pseudoxanthoma elasticum
2 44513202 ns T C 262 5 0 0.0094 1,075 3 0 0.0014 6.71429 3.615384 Cystinuria
2 71738977 ns G A 262 5 0 0.0094 1,074 4 0 0.0019 4.94737 3.615384 Muscular dystrophy. limb girdle/
Miyoshi myopathy
13 32914592 ns C T 262 5 0 0.0094 1,074 4 0 0.0019 4.94737 3.615384 Breast and/or ovarian cancer?
1 2234791 ns C T 260 7 0 0.0131 1,073 5 0 0.0023 5.69565 3.275 Cleft lip?
15 75012987 ns G T 233 33 1 0.0655 1,048 29 1 0.0144 4.54861 3.275 Colorectal cancer. reduced risk.
association with
17 73837042 ns T C 263 4 0 0.0075 1,076 2 0 9.00E-04 8.33333 2.884615 Hemophagocytic lymphohistiocytosis.
Familial
1 12064892 ns G A 261 6 0 0.0112 1,073 4 1 0.0028 4.00000 2.8 Charcot-Marie-Tooth disease 2a
21 44317156 ns A C 254 13 0 0.0243 1,070 8 0 0.0037 6.56757 2.43 Complex I deficiency
21 44317156 sp A C 254 13 0 0.0243 1,070 8 0 0.0037 6.56757 2.43 Complex I deficiency
(continued)
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(Fernandez et al. 2013) that can be relevant for diagnosis.
Variants associated with several cardiovascular pathologies
are also underrepresented in the Spanish population (supple
mentary table S1, Supplementary Material online).
In addition, there are 376 rare variants annotated to di-
verse diseases present only in one Spanish exome and absent
in all the 1000G individuals (supplementary table S1,
Supplementary Material online).
Allele Frequencies in Mendelian and Rare versus
Complex Diseases
Population differences in allele frequencies behave different
for complex than for mendelian and rare disease. Figure 2 and
supplementary figure S3, Supplementary Material online pro-
vide comparative information about allele frequencies of all
the diseases with more than five variants recorded in HGMD
and reveal an interesting trend. Most associations with com-
plex diseases show an almost identical distribution of fre-
quencies for all the variants in all the genes, including
associations with Alzheimer disease (fig. 2A), schizophrenia,
myocardial infarction, type 2 diabetes, obesity, or essential
hypertension, as well as most cancer associations (fig. 2B
and supplementary fig. S3, Supplementary Material online).
In sharp contrast, mendelian and rare diseases such as Marfan
syndrome (fig. 2C), Wilson disease, phenylketonuria, several
degenerative retinopathies such as age-related macular de-
generation and many others (fig. 2D), have remarkably
different allelic frequencies in the Spanish population com-
pared with the 1000G populations.
Relationship between Variant Frequencies and the
Prevalence of the Disease in the Population
To test whether population differences in frequencies of risk
alleles (for both, complex and mendelian diseases) result in
difference in the prevalence of the corresponding diseases, we
have collected data from the “Global Burden of Disease data-
base” (see Materials and Methods). We have found data on
“differences in disability-adjusted life years” (DALYs), a widely
used proxy of disease prevalence (Murray et al. 2015), for
several of the diseases analyzed here.
Interestingly, when the relative differences in allele fre-
quencies found in the Spanish population with respect to
European populations (TSI, FIN, GBR, and CEU) are compared
with the corresponding relative differences in DALYs between
Spain and the Central and East European populations, a re-
markable correspondence between both parameters was
found. Figure 3 depicts these relationships for the diseases
showing the most extreme differences in allelic frequencies
(Alzheimer, Attention deficit hyperactivity disorder,
Parkinson, Psoriasis, and Cardiovascular diseases). Observed
increases or decreases in allele frequencies in the Spanish
population relative to European populations correspond to




chr Start CT R A R/R R/A A/A MAF R/R R/A A/A MAF Ratio Ratio E HGMD_disease
18 58038832 ns T G 254 13 0 0.0243 1,069 9 0 0.0042 5.78571 2.43 Obesity. autosomal dominant?
12 6103650 ns G A 254 13 0 0.0243 1,069 9 0 0.0042 5.78571 2.43 Von Willebrand disease 1?
17 33430313 ns T C 254 13 0 0.0243 1,065 13 0 0.006 4.05000 2.43 Breast cancer. increased risk.
association with
13 49281554 ns A G 254 13 0 0.0243 1,061 17 0 0.0079 3.07595 2.43 Atopy. association with
12 6458350 ns A G 242 25 0 0.0468 1,055 22 1 0.0111 4.21622 2.34 Ischemic cerebrovascular events.
association with
17 42463054 ns G C 255 12 0 0.0225 1,068 10 0 0.0046 4.89130 2.25 Glanzmann thrombasthenia
12 22017410 sp C T 255 12 0 0.0225 1,066 12 0 0.0056 4.01786 2.25 Myocardial infarction. association with
12 22017410 ns C T 255 12 0 0.0225 1,066 12 0 0.0056 4.01786 2.25 Myocardial infarction. association with
1 158624528 ns G T 232 34 1 0.0674 1,042 34 2 0.0176 3.82955 2.246666 Spherocytosis. association with?
22 46614274 ns C G 224 40 3 0.0861 1,027 49 2 0.0246 3.50000 2.1525 Elevated plasma lipid conc. assoc.
in diabetes
5 82491674 ns T C 233 34 0 0.0637 1,042 36 0 0.0167 3.81437 2.123333 Lung cancer. susceptibility to.
association with
19 36341311 ns T A 256 11 0 0.0206 1,072 6 0 0.0028 7.35714 2.06 Focal segmental glomerulosclerosis
5 151202476 ns C T 256 11 0 0.0206 1,066 12 0 0.0056 3.67857 2.06 Hyperekplexia
5 110428060 ns T C 256 11 0 0.0206 1,064 14 0 0.0065 3.16923 2.06 Glaucoma. primary open angle.
association with?
13 78475230 ns C T 256 11 0 0.0206 1,064 14 0 0.0065 3.16923 2.06 Hirschsprung disease
1 227170648 syn C T 257 9 1 0.0206 1,063 15 0 0.007 2.94286 2.06 Ubiquinone deficiency with
cerebellar ataxia
NOTE.—The first column indicates the chromosome; the second column indicates the position of the variant; the third column labeled CT, contains the consequence type,
which are ns, nonsynonymous SNV; syn, synonymous; sg, stop gain; sp, variant affecting splicing; nc, ncRNA_exonic; the fourth column, labeled R, contains the reference allele in
the position; the fifth column, labeled A, contains the alternative allele; the three following columns (sixth, seventh, and eight), labeled R/R, R/A, and A/A contain the number of
individuals in which a reference homozygote (R/R), heterozygote (R/A) or an alternative homozygote (A/A) are found in the Spanish population, respectively; the ninth
column, labeled MAF, contains the alternative allele frequency in the Spanish population; the three following columns (tenth, 11th, and 12th) contain the number of individuals
in which a reference homozygote (R/R), heterozygote (R/A), or an alternative homozygote (A/A) are found in the 1000G populations; the 13 column, labeled Ratio, contains the
ratio between the Spanish and the 1000G MAFs, the 14th column, labeled Ratio E, contains the ratio between the Spanish MAF and the 1000G MAFs of populations with
European ancestry only; and finally, the 15th column, labeled as HGMD disease, contains the description of the disease caused by the variant, which can be a causal effect, or an
association (when the description ends in “association with”) and can also be uncertain (then, the definition includes a question mark).
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Variants of Pharmacogenetic Relevance
The 267 exomes of the MGP population were screened for
variants of pharmacogenetics relevance. In particular, we con-
sidered variants which affect drug binding sites, thus poten-
tially disrupting the binding domain, without being
deleterious to the protein. These variants will likely cause total
or partial drug binding inhibition with potential effects such
as resistance to treatments or may even cause adverse effects.
There are 112 variants affecting well defined drug binding
domains (Hopkins and Groom 2002). Among these, 31 are
predominant in the Spanish population, with MAFs 1.5-fold
higher than those observed in the 1000G populations (sup
plementary table S2, Supplementary Material online). For ex-
ample, the gene CYP11B2 from the Cytochrome P450 family is
affected in the binding site of different drugs (Eplerenone,
Etomidate, Hydrocortisone, Metoclopramide, Metyrapone)
used to treat a variety of diseases (including heart failure or
hypercortisolism) or symptoms (antiemetic), by a nonsynon-
ymous mutation which has a MAF prevalence in the Spanish
population 15 times higher than that observed in the 1000G
populations. Binding sites for several statins, drugs for mi-
graine treatment, analgesics, and others (up to a total of
31) were also found to be affected by nonsynonymous vari-
ants present in the Spanish population at higher frequencies
(over 1.5 times higher) than in the 1000G populations.
Binding sites for several natural substances were also com-
paratively more affected by nonsynonymous variants in the
MGP population than in the 1000G populations, including
FIG. 2. Comparison of allelic frequencies described in HGMD between the MGP Spanish population and the 1000 genomes populations in four
diseases with more than five variants. Upper left panel shows the frequencies in the Spanish MGP samples found for all the variants associated with
Alzheimer disease in HGMD (X axis) versus the corresponding frequencies observed in all the individuals of the 1000 genomes populations (Y axis).
Upper right panel presents a similar plot for variants described in HGMD as associated to leukemia risk. Lower left and right panels depict the same
relationship for two rare diseases, Marfan syndrome, and age-related macular degeneration, respectively.
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Ursodeoxycholic acid, Vitamin A, Choline (B-vitamin com-
plex), L-Tryptophan, Glycine, and Tetrahydrobiopterin,
among others.
On the other hand, there are also 46 drug and natural
compound binding sites that were remarkably less affected
by variants in the Spanish population than in the 1000G
reference population (with MAFs which are less than one-
half that observed in 1000G; see supplementary table S2,
Supplementary Material online). The fact that different
drug binding sites are affected at different frequencies in dif-
ferent populations could account for population-specific dif-
ferences in sensitivity, efficiency, and even resistance to drugs
or their adverse effects.
Supplementary table S2, Supplementary Material online
lists other natural substances of interest. Since the binding
sites of these substances may have been under negative se-
lective pressure we studied possible deviations from the
Hardy–Weinberg equilibrium which could be caused by a
deleterious allele. Only a few of them (32; see supplementary
table S2, Supplementary Material online) deviated signifi-
cantly from the equilibrium, which suggests that either the
majority of variants do not deactivate the binding sites or that
there are other binding sites which compensate for their pu-
tative loss.
Among the variants that deviate from the Hardy–
Weinberg equilibrium there is one that affects the binding
site for several compounds, including Glutamic Acid, in the
gene GRIN3A. This gene is a glutamate receptor known to be
under geographically localized positive selection, and to be
related to obesity, coronary artery calcification, and Thiazide-
induced adverse metabolic effects in hypertensive patients
(Colonna et al. 2014). Moreover, four variants which affect
three binding sites for NADH display significantly lower fre-
quencies in the Spanish population when compared with the
1000G populations and one of them, located in the SORD
gene, significantly deviates from the Hardy–Weinberg equi-
librium (adjusted P value¼ 0.00005). The same occurs with a
binding site for L-Phenylalanine, L-Tyrosine, and
Tetrahydrobiopterin, to which the antihypertensive drug
Metyrosine (a tyrosine hydroxylase enzyme inhibitor), also
binds (supplementary table S2, Supplementary Material on-
line). Interestingly, a variant which affects the binding site of
two diuretic drugs (Amiloride, Triamterene) also significantly
deviates from the Hardy–Weinberg equilibrium (adjusted P
value < 0.00005). In these three cases, the 1000G population
presented significantly higher MAFs and did not deviate from
the Hardy–Weinberg equilibrium. We also observed that the
corresponding frequencies in the Exome Variant Server (Fu
et al. 2013) are similar to the 1000G population.
Selective Pressures
We used the McDonald–Kreitman test (MKT) (McDonald
and Kreitman 1991) to search for signals of natural selection
acting on genes. Although a total of 145 genes, corresponding
to 365 different transcripts showed events of positive selec-
tion (supplementary table S3, Supplementary Material online
lists genes with a nominal P value< 0.05), only MUC4 was still
significant after multiple testing correction (adjusted P value
¼ 1.7  106). Interestingly, MUC4 has a variant associated
with Ulcerative colitis (HGMD ID CM066583) which is signif-
icantly underrepresented in the MGP population (adjusted P
value ¼ 0.00208) (supplementary table S1, Supplementary
Material online).
To find signals of recent positive selection FST values were
calculated as a measurement of population differentiation
between the MGP population and all the European 1000G
populations (TSI, FIN, GBR, and CEU, excluding IBS). As ex-
pected, the mean FST between these two groups was low
(0.007) although several loci showed extreme values (supple
mentary fig. S4, Supplementary Material online for a histo-
gram of the FST distribution). SNPs with exceptionally high
FST values (FST > 0.2) were considered candidates for selec-
tion (152 SNPs, 0.41% of the SNPs, see supplementary table
S4, Supplementary Material online). Interestingly, a SNP
(rs2550270) in the gene MUC4 presented an extreme FST
value (FST¼ 0.3; see supplementary table S4, Supplementary
Material online) but it is not the same one associated with
Ulcerative colitis.
Increased Resolution Using Local Variability
to Find Disease Genes
Knowledge of local variability can also have a practical appli-
cation in clinical research. The systematic use of WES for
finding disease genes has proven to be very successful in dis-
covering new disease genes (Bamshad et al. 2011). Since
exomes contain a vast number of mutations the number of
candidate disease variants must be reduced in a process of
FIG. 3. Comparison of the relative prevalence and MAFs for several of
the diseases showing the most extreme differences in allelic frequen-
cies. The two first bars in each disease represent the log2 of the ratios
of prevalence of the disease (DALYs) in Spain with respect to the
corresponding prevalence in Central and East Europe, respectively,
and the third bar represents the log2 of the ratio of the MAF of alleles
of the disease in Spain and the corresponding MAF in the European
populations of 1000G. The diseases are abbreviated as: Alzheimer
(AD), Attention deficit hyperactivity disorder (ADHD), Parkinson
(PD), Psoriasis (PSO), and Cardiovascular diseases (CAD).
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prioritization involving a series of filters to exclude variants
that are not likely to cause disease. One of the most stringent
filters involves discarding variants which are present in the
population at frequencies similar to or above the prevalence
of the disease itself (Goldstein et al. 2013). Since local popu-
lation frequencies are not typically available, general reposi-
tories, such as 1000G and others, are used. As a practical
demonstration of the importance of knowledge about local
variability, here we describe a specific example of a large family
affected by autosomal-dominant retinitis pigmentosa (adRP;
OMIM 268000). The use of the conventional consecutive fil-
tering approach, implemented in the BiERApp tool (Aleman
et al. 2014) which includes a specific filtering step for local
variants, enormously increases the discovery power of the
methodology.
The family, of Spanish origin, comprises three generations
and our study included seven affected members (fig. 4A), who
were clinically diagnosed with adRP, following ophthalmic
criteria as previously described (Mendez-Vidal et al. 2013).
All the affected individuals were derived from the
Ophthalmology Department of the Genetic, Reproduction
and Fetal Medicine Department at the Hospital Virgen del
Rocio (Seville, Spain). The family did not present any known
mutation for adRP and none of their members was included
in the 267 MGP samples analyzed. The KING program
(Manichaikul et al. 2010) was used to confirm the absence
of any possible kinship between the family studied and any of
the samples in the MGP population.
WES of all the affected patients as well as the grandmother
(with a genetic background common to all of them) was
carried out as described in Materials and Methods. The se-
lection of heterozygous variants segregating with the pedigree
in figure 4A raised many possible candidates. Since the inci-
dence of the disease is below 1 in 4,000 (Ayuso and Millan
2010), variants present in normal populations at frequencies
higher than 0.001, the lowest frequency that can be obtained
from 1000G (Durbin et al. 2010) populations, were discarded
as putative disease-causing variants. The dark blue bars in
figure 4B correspond to the number of variants which do
not appear in the 1000G populations but that still segregate
with the family when a growing number of affected individ-
uals (from one to seven) are used to filter out variants. When
we instead used the local Spanish population (MGP; se-
quenced here) to filter out variants present in the healthy
population (pale blue bars in fig. 4B) the filtering power was
strongly increased. We used the BiERapp tool (Aleman et al.
2014) to apply consecutive filters (segregation along the fam-
ily pedigree, predicted pathogenicity, and population fre-
quency) to select potential disease variants and genes. The
analysis of variants shared by the seven affected members
after filtering out those present in the Spanish population
rendered a total of 7 possible variants corresponding to 7
candidate genes. We then performed cosegregation analysis
using DNA samples from available family members which
confirmed the presence of the variant in the family. The novel
variant identified was subsequently screened in 200 healthy
matched control subjects by Sanger sequencing, confirming
its absence and thus validating the c.937-2_944del variant as a
novel causal RP mutation. This variant produces the loss of a
cryptic splice acceptor site in intron 4–5 of the RHO gene, and
therefore the use of a cryptic splice site upstream of the
normal acceptor splice site results in a truncated protein
which might be subject to nonsense-mediated decay in these
patients. Sanger sequencing was used to validate the muta-
tion found. For this purpose, specific primers encompassing
the RHO intron 4–exon 5 junction were designed using the
Primer3 software (Rozen and Skaletsky 2000) with sense and
antisense sequences TACAGAACACCCTTGGCACA and
AGGTGTAGGGGATGGGAGAC, respectively, rendering an
amplicon length of 424 bp and a Tm of 62 C.
Discussion
Our work describes with precision the level of variation ob-
served in the genomic coding regions of 267 unrelated
FIG. 4. Effect of filtering out variants with high MAFs using frequency
data inferred either from the available databases (1000G) or from the
MGP Spanish population sequenced here. (A) Pedigree of the family
studied with seven members affected by adRP. (B) Segregation anal-
ysis across the family was carried out, followed by a step filtering out
the variants found in a reference population with a MAF incompat-
ible with the observed prevalence of adRP. The plot represents the
number of candidate variants that segregate with the family as a
growing number of affected members were used to select the variants
(from one to seven) and when two reference populations (1000G,
pale blue and the MGP Spanish local population, dark blue) were used
to filter out variants with MAFs that were too high to be compatible
with the prevalence observed for the disease (>0.001 in 1000G and
>0.004 in the MGP population, respectively). The filtering effect on
the local Spanish population was drastically more stringent than for
the 1000G population.
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healthy Spanish individuals, which makes it the largest study
to date on local variation in a single population. Thanks to
large sample size, the conclusions can be considered more
significant than those obtained from general studies involving
multiple populations with smaller numbers of individuals
(Durbin et al. 2010; Li et al. 2010; Corona et al. 2013; Fu
et al. 2013; Moreno-Estrada et al. 2013). However, it must
also be taken into account that, while the population-specific
results can be considered robust, the existence of a certain
bias in the comparative analysis of the Spanish and the 1000G
populations, derived from the fact that they are independent
experiments, using different sequencing technologies and
sampling strategies cannot be completely ruled out.
Here, we document that while the polymorphic variants
private to the Spanish population are almost completely de-
scribed in this work by analyzing only 267 individuals (fig. 1),
the rate of discovery of new rare variants with increasing
numbers of sequenced individuals was still far from reaching
a plateau. Although many Spanish rare variants remain to be
discovered, the use of the population frequencies obtained in
this work does already afford increased ability (relative to the
use of 1000G project data) to filter candidate variants in a
Spanish family which could otherwise be interpreted as pos-
sible disease variants (fig. 4).
As expected given the magnitude of the rare variation
discovered in the Spanish population, a significant number
of variants were related to diseases (Kryukov et al. 2007;
MacArthur and Tyler-Smith 2010; MacArthur et al. 2012;
Xue et al. 2012). When the frequencies of disease variants
or disease-risk variants in the Spanish population are com-
pared with the corresponding frequencies observed in the
1000G populations an interesting trend emerges: complex
disease variants seem to have similar allelic frequencies in
both the MGP Spanish samples and 1000G populations. In
contrast, mendelian or rare diseases tend to present dissimilar
allelic frequency distributions (supplementary fig. S3,
Supplementary Material online). In these, and other similar
diseases, the most prevalent alleles are different in distinct
populations. This observation agrees with the fact that, while
high-frequency variants and variants underlying complex dis-
eases tend to be shared across populations (Marigorta and
Navarro 2013), low-frequency alleles tend to be private
(Casals et al. 2013). This, together with recent discoveries of
new population-specific variants causal of inherited diseases,
such as retinopathies (Méndez-Vidal et al. 2014), strongly
points at a crucial role of private mutations in the configura-
tion of the mutational spectrum of certain diseases. In other
words, geographic heterogeneity in the genetic architecture
of disease, that is, the fact that different variants, often in
different genes, can cause common multigenic diseases in
different populations (Fernandez et al. 2013), may be more
frequent than expected, again highlighting the need for local
variation catalogs (Bustamante et al. 2011).
Since the use of drugs is very recent in evolutionary terms, it
is expectable that the observed differences in frequencies in the
variants located in a number of drug binding sites are due to
population founder effects rather than any selective processes.
However, once an area of a protein’s surface turns out to be a
drug binding site it becomes relevant from a clinical perspec-
tive. We observed a total of 121 variants affecting the binding
sites of different drugs. We also observed differences in the
frequencies of variants affecting the binding sites of some nat-
ural products, such as Vitamin A, Choline, L-Tryptophan,
Glycine, etc. In this case, some selective effect against mutations
in the binding sites could be hypothesized. It is known that
genes related to xenobiotic metabolism (Arbiza et al. 2006),
pathogen adaptation to (Karlsson et al. 2014), or dietary change
(Luca et al. 2010) are under selective pressures due to their
relationship to disease in modern humans (Babbitt et al. 2011;
Engelken et al. 2014). However, the study of Hardy–Weinberg
equilibrium does not support the existence of selective pressure
against any of the alleles for most of the cases of variants
affecting the binding sites of natural products. Therefore, either
the power of the test is too low or many of the studied vari-
ations are unlikely to inactivate these binding sites. In this study
only three specific binding sites, corresponding to NADH, L-
Phenylalanine, and L-Tyrosine, were affected by variants that
significantly deviate from the Hardy–Weinberg equilibrium,
thus suggesting the existence of some type of selection against
such variants in the Spanish population which has not been
detected in the 1000G project.
Our findings clearly highlight the importance of local var-
iability in any study which attempts to relate genotype to
phenotype, specifically when the phenotype is a disease. In
the example given, the local variability filter discarded five
times more candidate variants (false positives) than the filter
based only on population allelic frequencies derived from
foreign populations (1000G). Although the need for popula-
tion-specific catalogs of genetic variation has been previously
noted (26), our results clearly reveal the quantitative magni-
tude of the differences expected between the use of a general
population and a local population, and its impact on clinically
relevant human variation. To foster research about other
pathologies, we have made publicly available through the
Spanish population variant server web page (http://spv.babe
lomics.org/, last accessed January 28, 2016) all the relevant
information on population frequencies for the 170,888 vari-
ant positions found in this study.
Materials and Methods
Human Subjects
Following informed consent, 267 unrelated samples of
Spanish origin, which were phenotyped as healthy, were ob-
tained and further anonymized and sequenced. The criteria
followed for declaring them healthy were the absence of cur-
rent known disease or genetic conditions in the family history,
although diseases appearing at older ages cannot be com-
pletely ruled out. The samples were collected in 2004 and
stored in the Biobank at the Hospital Virgen del Rocio (Seville,
Spain), where they were routinely used as controls for geno-
type studies. Their geographical origin corresponds mainly to
the North (Galicia and Catalonia), the center (Madrid), and
the South of Spain (Andalucia). The sampling centers were
the Camas and the Candelaria hospitals (Andalucia), the Dr
Joan Vilaplana Hospital (Cataluña), the Hospital Clı́nico
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Universitario de Santiago (Galicia), and the Almodeva
Hospital (Madrid). The number of individuals sampled in
each location was approximately proportional to the popu-
lations of the corresponding regions. Because the samples
were sequenced in the context of the Medical Genome
Project, we called this population MGP. Samples were ob-
tained in accordance with the approved protocols of the
respective institutional review boards for the protection of
human subjects. The study conformed to the tenets of the
declaration of Helsinki.
Human Populations
A total of 13 human populations were used in this study
which included: European populations TSI from Tuscany in
Italy (98 samples), FIN Finnish from Finland (93 samples), GBR
British from England and Scotland (89 samples), CEU resi-
dents of Utah (CEPH collection) with northern and western
European ancestry (85 samples), and the IBS, from Spain (14
samples); Asian populations CHB Han Chinese in Beijing,
China (97 samples), CHS southern Han Chinese (100 sam-
ples), and JPT Japanese in Tokyo, Japan (89 samples);
American populations were MXL Mexican Ancestry in Los
Angeles, CA (66 samples), PUR Puerto Rican in Puerto Rico
(55 samples), and CLM Colombian in Medellin, Colombia (60
samples); and African populations were YRI Yoruba in Ibadan,
Nigeria (88 samples), LWK Luhya in Webuye, Kenya (97 sam-
ples), and ASW African Ancestry in Southwest United States
(61 samples). The exome sequences of all the individuals
corresponding to the 13 populations were downloaded
from the 1000 genomes web page (http://www.
1000genomes.org/, last accessed January 28, 2016) in
multisample variant calling format (VCF).
Finally, we used the MGP Spanish samples (367), totaling
1,359 studied individuals.
Construction of DNA Libraries and Sequencing
Library preparation and exome capture were carried out ac-
cording to a protocol based on the Baylor College of Medicine
protocol version 2.1 (with several minor modifications). First,
5mg of input genomic DNA is sheared, end-repaired and
ligated with specific adaptors. A fragment size distribution
ranging from 160 to 180 bp after shearing and 200–250 bp
after adaptor ligation was verified using a Bioanalyzer
(Agilent). The library is amplified using a precapture linker-
mediated polymerase chain reaction (LM-PCR) using a
FastStart High Fidelity PCR System (Roche) and barcoded
primers. After purification, 2mg of LM-PCR product are hy-
bridized to NimbleGen SeqCap EZ Exome libraries V3. After
washing, amplification is performed by postcapture LM-PCR
using a FastStart High-Fidelity PCR System (Roche). Capture
enrichment is measured by qPCR according to the
NimbleGen protocol. The successfully captured DNA is mea-
sured by Quant-iT PicoGreen dsDNA reagent (Invitrogen)
and subjected to standard sample preparation procedures
for sequencing on the SOLiD 5500xl platform as recom-
mended by the manufacturer. Emulsion PCR is performed
on the E80 scale (about 1 billion template beads) using a
concentration of 0.616 pM that contains 4 equimolecular
pooled libraries of enriched DNA. After breaking and enrich-
ment, 276 million enriched template beads are sequenced
per lane on a 6-lane SOLiD 5500xl slide.
Sequencing Data Analysis
A customized pipeline for processing the raw sequences
(FastQ files) was applied. First, sequence reads were aligned
to the reference human genome build GRCh37 (hg19) by
using the SHRiMP tool (Rumble et al. 2009). Correctly
mapped reads were further filtered with SAMtools (Li et al.
2009), which was also used for sorting and indexing mapping
files. Only high quality sequence reads mapping to the refer-
ence human genome in unique locations were used for calling
variants. The Genome Analysis Toolkit (GATK) (McKenna
et al. 2010) was used to realign the reads around known indels
and for base quality score recalibration. Identification of single
nucleotide variants and indels was performed using GATK
standard hard filtering parameters (DePristo et al. 2011). The
result of this pipeline was a VCF file for each sequenced
sample.
All the VCF files were then scanned for disease variants
(variants with a reported association with a disease). The
program VARIANT (Medina et al. 2012), which contains an-
notations from the latest versions of Ensembl Variation
(Flicek et al. 2012), Uniprot (Magrane and Consortium
2011), dbSNP (Sherry et al. 2001), and HGMD (Stenson
et al. 2009) was used for this purpose. Positions that were
not determined (because of any quality control problems or
lack of coverage) for more than the 75% of the samples
analyzed were not considered in the study.
Tests for Selection
We used the MKT (McDonald and Kreitman 1991) to test for
possible selective pressures in the MGP population. The MKT is
based on the comparison of the ratio of nonsynonymous to
synonymous SNPs between species (Dn/Ds) and within species
(Pn/Ps). Assuming that synonymous mutations behave neu-
trally, a higher Dn/Ds than Pn/Ps ratio is expected in case of
adaptive selection, because mutations that are positively se-
lected in a population, and therefore rise quickly to fixation,
would contribute more to divergence than to polymorphism.
We estimated the per gene proportion of base substitutions
fixed by natural selection, a (Smith and Eyre-Walker 2002) with:
/¼ 1 DsPn
DnPs
where Pn and Ps are the total number of nonsynonymous and
synonymous polymorphisms and Dn and Ds the number of
nonsynonymous and synonymous divergent differences, re-
spectively. Significant positive values of a (Dn/Pn > Ds/Ps)
indicate an excess of fixation of nonneutral mutations sug-
gesting that positive selection is driving a change in this gene.
Measures of polymorphism in the MGP population and
human–chimpanzee divergence were used to calculate a
for all coding sequences. Sites diverging between panTro2
and hg19 were inferred on the Galaxy website (http://main.
g2.bx.psu.edu/, last accessed January 28, 2016) using the
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regional variation/fetch substitutions from the pairwise align-
ments tool. For each identified nucleotide substitution, pair-
wise alignments of panTro2/hg19 were downloaded using the
fetch alignments/fetch pairwise MAF blocks tool for our set of
genomic intervals.
In addition, to detect signals of recent positive selection we
calculated the FST values (Weir and Cockerham 1984) be-
tween the MGP population and all European 1000G popula-
tions (TSI, FIN, GBR, and CEU, excluding IBS) as a measure of
population differentiation between two populations . Only
polymorphic positions with maximum of 75% missing data
and with a MAF of at least 10% were used. These SNPs were
assigned to genes using the SNP Nexus webtool (Dayem Ullah
et al. 2012). In the cases in which SNP Nexus could not assign
genes to SNPs, they were assigned manually using the
Ensembl Biomart (GRCh37 archive site) (Kinsella et al.
2011) and dbSNP (Sherry et al. 2001) websites.
Finally, as additional evidence for possible selection against
the alternative allele homozygote, deviations from the
Hardy–Weinberg proportions were tested for all the variants
with a v2 test (Wigginton et al. 2005).
Statistical Analysis
The program SNPRelate (Zheng et al. 2012) was used to carry
out principal component analyses.
A v2 test was used to assess the significance of the differ-
ences in allele frequencies in the MGP population when com-
pared with the 1000G populations.
Multiple testing adjustments were performed using the
False Discovery Rate method (Benjamini and Hochberg 1995).
The KING program (Manichaikul et al. 2010), with the
parameters—unrelated—degree 2 (which extracts a list of
individuals with no first- or second-degree relationship be-
tween any pairs), was used to confirm that all the samples
used in the study were unrelated individuals. The VCF file
from the sequencing data was converted into the PLINK bi-
nary format required by KING via VCFtools (Danecek et al.
2011).
Functional enrichment was assessed using the FatiGO (Al-
Shahrour et al. 2004) as implemented in Babelomics (Alonso
et al. 2015). We also applied a gene set enrichment analysis as
described in Daub et al. (2013) using the sum of FST values as
summary statistic of genes in a gene set.
Disease Variants, Genes, and Definitions
Disease annotations were taken from HGMD commercial
release 2011.4 (Stenson et al. 2009). A total of 76,128 anno-
tations, including 69,965 unique variants (denoted by the
chromosome and start position in chromosomal coordina-
tes) are contained in the database. HGMD incorporates dif-
ferent types of variants that include not only single base pair
substitutions and indels affecting coding regions but also var-
iants with consequences for mRNA splicing and regulatory
abnormalities. HGMD stores only disease-causing mutations
and disease-associated/functional polymorphisms but also
includes a number of SNPs from GWAS, although only if there
is evidence of an effect on function. Since not all the HGMD
identifiers were still public at the time of writing this article,
we included the source from which the evidence of the mu-
tation was taken (a publication) in the tables presented here.
The DALYs were taken as an approximation to the prev-
alence of the diseases. DALYs from the “Global Burden of
Disease” Study (Murray et al. 2015) were obtained from the
repository of this study (http://www.healthdata.org/gbd, last
accessed January 28, 2016).
Definition of Deleterious Variants
Variants with “synonymous” or “unknown” functional con-
sequences were filtered out. Then, using the VARIANT soft-
ware (Medina et al. 2012) the putative impact and damaging
effect of the variants on protein function was predicted by
computing both SIFT (Kumar et al. 2009) and Polyphen
(Ramensky et al. 2002) damage scores and the phastCons
(Siepel et al. 2005) conservation score. Since the conservation
score is the only parameter applicable to any type of position,
it was used as a primary filter. Variants with a phastCons
conservation score higher than 200 were selected as damag-
ing variants. SIFT and Polyphen scores were only used when
available. SIFT scores lower than 0.05 and/or Polyphen scores
higher than 0.95 indicate that a variant is most likely delete-
rious. Variants with at least two of the three pathogenicity
predictors indicating a potential deleterious effect were con-
sidered deleterious.
Drug Targets
A list of 130 drug binding domains was extracted from “The
druggable genome” publication (Hopkins and Groom 2002).
The domains were mapped in the corresponding proteins us-
ing InterPro (version 47.0, 20 May 2014) (Hunter et al. 2012).
To define what domains were affected by substitutions
that disrupt the domain without being deleterious for the
protein only SNVs mapping to drug binding domains with
SIFT and Polyphen values outside the deleteriousness range
(i.e., SIFT scores higher than 0.05 and Polyphen scores lower
than 0.95) were considered.
Supplementary Material
Supplementary tables S1–S4 and supplementary figures
S1–S4 are available at Molecular Biology and Evolution online
(http://www.mbe.oxfordjournals.org/).
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